Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Fanale

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
International Journal of Molecular Sciences|May 23, 2017
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future PerspectivesSalvatore Giovanni Vitale, Antonio Simone Laganà, Stella Capriglione, et al.
Critical Reviews in Oncology/Hematology|August 3, 2023
Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?Daniele Fanale, Lidia Rita Corsini, Erika Pedone, et al.
Critical Reviews in Oncology/Hematology|June 6, 2021
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitorsLorena Incorvaia, Giorgio Madonia, Lidia Rita Corsini, et al.
Critical Reviews in Oncology/Hematology|February 12, 2022
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaningDaniele Fanale, Alessia Pivetti, Daniela Cancelliere, et al.
Analytical Cellular Pathology (Amsterdam)|October 21, 2015
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Daniele Fanale, Giuseppe Bronte, Francesco Passiglia, et al.
Therapeutic Advances in Medical Oncology|January 6, 2021
<i>BRCA1/2</i> pathogenic variants in triple-negative <i>versus</i> luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patientsLorena Incorvaia, Daniele Fanale, Marco Bono, et al.
Critical Reviews in Oncology/Hematology|January 16, 2022
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?Daniele Fanale, Lidia Rita Corsini, Raimondo Scalia, et al.
Frontiers in Oncology|June 28, 2021
Prevalence and Spectrum of Germline <i>BRCA1</i> and <i>BRCA2</i> Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the GenomeDaniele Fanale, Alessia Fiorino, Lorena Incorvaia, et al.
NPJ Precision Oncology|September 5, 2024
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumorsLorena Incorvaia, Tancredi Didier Bazan Russo, Valerio Gristina, et al.
Frontiers in Oncology|October 10, 2022
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?Daniele Fanale, Lidia Rita Corsini, Chiara Brando, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
International Journal of Molecular Sciences|May 23, 2017
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future PerspectivesSalvatore Giovanni Vitale, Antonio Simone Laganà, Stella Capriglione, et al.
Critical Reviews in Oncology/Hematology|August 3, 2023
Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?Daniele Fanale, Lidia Rita Corsini, Erika Pedone, et al.
Critical Reviews in Oncology/Hematology|June 6, 2021
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitorsLorena Incorvaia, Giorgio Madonia, Lidia Rita Corsini, et al.
Critical Reviews in Oncology/Hematology|February 12, 2022
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaningDaniele Fanale, Alessia Pivetti, Daniela Cancelliere, et al.
Analytical Cellular Pathology (Amsterdam)|October 21, 2015
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Daniele Fanale, Giuseppe Bronte, Francesco Passiglia, et al.
Therapeutic Advances in Medical Oncology|January 6, 2021
<i>BRCA1/2</i> pathogenic variants in triple-negative <i>versus</i> luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patientsLorena Incorvaia, Daniele Fanale, Marco Bono, et al.
Critical Reviews in Oncology/Hematology|January 16, 2022
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?Daniele Fanale, Lidia Rita Corsini, Raimondo Scalia, et al.
Frontiers in Oncology|June 28, 2021
Prevalence and Spectrum of Germline <i>BRCA1</i> and <i>BRCA2</i> Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the GenomeDaniele Fanale, Alessia Fiorino, Lorena Incorvaia, et al.
NPJ Precision Oncology|September 5, 2024
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumorsLorena Incorvaia, Tancredi Didier Bazan Russo, Valerio Gristina, et al.
Frontiers in Oncology|October 10, 2022
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?Daniele Fanale, Lidia Rita Corsini, Chiara Brando, et al.
Pageof 7